- Home
- REAL vs SEPN Comparison
REAL vs SEPN Comparison
Compare REAL & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- SEPN
- Stock Information
- Founded
- REAL 2011
- SEPN 2022
- Country
- REAL United States
- SEPN United States
- Employees
- REAL N/A
- SEPN N/A
- Industry
- REAL Other Specialty Stores
- SEPN
- Sector
- REAL Consumer Discretionary
- SEPN
- Exchange
- REAL Nasdaq
- SEPN NYSE
- Market Cap
- REAL 982.8M
- SEPN 1.0B
- IPO Year
- REAL 2019
- SEPN 2024
- Fundamental
- Price
- REAL $9.33
- SEPN $25.90
- Analyst Decision
- REAL Buy
- SEPN Strong Buy
- Analyst Count
- REAL 6
- SEPN 4
- Target Price
- REAL $7.04
- SEPN $43.67
- AVG Volume (30 Days)
- REAL 3.8M
- SEPN 493.8K
- Earning Date
- REAL 11-04-2024
- SEPN 02-15-2025
- Dividend Yield
- REAL N/A
- SEPN N/A
- EPS Growth
- REAL N/A
- SEPN N/A
- EPS
- REAL N/A
- SEPN N/A
- Revenue
- REAL $579,862,000.00
- SEPN $981,000.00
- Revenue This Year
- REAL $11.26
- SEPN $406.62
- Revenue Next Year
- REAL $8.81
- SEPN N/A
- P/E Ratio
- REAL N/A
- SEPN N/A
- Revenue Growth
- REAL 2.52
- SEPN N/A
- 52 Week Low
- REAL $1.52
- SEPN $18.62
- 52 Week High
- REAL $9.78
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- REAL 73.17
- SEPN N/A
- Support Level
- REAL $8.54
- SEPN N/A
- Resistance Level
- REAL $9.73
- SEPN N/A
- Average True Range (ATR)
- REAL 0.73
- SEPN 0.00
- MACD
- REAL -0.00
- SEPN 0.00
- Stochastic Oscillator
- REAL 88.10
- SEPN 0.00
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the us, generating $1.7 billion in 2023 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 34% of net merchandise value, which excludes returns, cancellations, and first-party sales.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.